SPONSORED CONTENT
The implementation of Medicare’s Maximum Fair Price (MFP) program under the Inflation Reduction Act has introduced one of the most operationally significant changes to pharmaceutical reimbursement in decades, one that has important ramifications for 340B
…
Q: Tell us some interesting details about your company’s history.
At RxParadigm, we like to think we’ve always been a few steps ahead, not because we have a crystal
…
Q: What is the primary problem RxParadigm’s Tungsten+PLUS™ solves?
Tungsten+PLUS™ is a transparent platform designed to eliminate 340B duplicate discounts, reconcile Inflation Reduction Act (IRA)-driven…
Read More »SPONSORED CONTENT
RxParadigm’s Tungsten+PLUS technology is a purpose-built, enterprise-grade platform designed to operationalize Medicare Maximum Fair Price (MFP) effectuation and 340B rebate claims adjudication at scale. The platform, which serves as a neutral clearinghouse rather than being controlled
…SPONSORED CONTENT
The U.S. drug pricing infrastructure is entering a transformative era. On August 1, 2025, the Health Resources and Services Administration (HRSA) announced a voluntary 340B Rebate Model Pilot, aligned with the Inflation Reduction Act’s Maximum Fair Price
… Q: Tell us some interesting details about your company’s history.
RxParadigm was built to stay ahead of the curve in healthcare’s most complex arenas. From our inception, we’ve focused
…SPONSORED CONTENT
The 340B program has experienced significant changes and disruptions over the past five years, prompting both legislative and judicial action. On May 15, a federal judge rejected efforts by four manufacturers to
… Q: Tell us some interesting details about your company’s history.
RxParadigm, founded by industry veteran Mesfin Tegenu, is dedicated to developing technology solutions that streamline the drug supply chain
…SPONSORED CONTENT
Please join on us April 22nd at 1:00 p.m. EST for the third installment of RxParadigm’s 340B Clearinghouse Webinar Series.
… SPONSORED CONTENT
The evolving landscape of pharmaceutical pricing and reimbursement models presents complex challenges for manufacturers and pharmacies. One of the most significant developments is the introduction of the Inflation Reduction Act (IRA) and its Maximum Fair Price (MFP) provisions, aimed at
…
